Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117709 · ClinicalTrials.gov registry record · NA
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 73
- Enrollment target
NCT06117709 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 73 participants.
The verdict
NCT06117709, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
Interventions
- BEHAVIORAL I-STAMP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2026-05 |
| Est. Completion | 2026-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06117709
The ClinicalTrials.gov registry entry for NCT06117709 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I-STAMP is the first listed.
NCT06117709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06117709 about?
NCT06117709 is a clinical study titled "Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing". The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
What is the current status of trial NCT06117709?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 73 participants. The study started on 2026-05. Estimated completion is 2026-08-30.
What interventions are being tested in trial NCT06117709?
The interventions under investigation include: I-STAMP (BEHAVIORAL).
Who is sponsoring clinical trial NCT06117709?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.